SCHEMBL19082426

SCHEMBL19082426

c1ccc2c(c1)ccc1c2sc2ccc3c4cc(-c5c6ccccc6c(-c6ccc7c(c6)sc6ccccc67)c6ccccc56)ccc4sc3c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP1A1 P04798 5/20 0.37
CYP1B1 Q16678 5/20 0.37
CYP1A2 P05177 4/20 0.37
ALOX5 P09917 1/20 0.36
GPR3 P46089 1/20 0.36
NQO1 P15559 1/20 0.35
NQO2 P16083 1/20 0.35
PTPN1 P18031 1/20 0.34
POLB P06746 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
TNKS O95271 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
MEN1 O00255 1/20 0.32
DUSP3 P51452 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17247189 0.96 MAPT (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL17944901 0.96 MAPT (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19082425 0.95 MAPT (0.40) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL17247149 0.93 CYP1A1 (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19082422 0.91 MAPT (0.39) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19110330 0.91 MAPT (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL17944696 0.91 MAPT (0.42) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL17944975 0.90 CYP1A1 (0.43) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19082120 0.90 CYP1A1 (0.39) SMN1; SMN2CYP1A1CYP1B1CYP1A2ALOX5
SCHEMBL19082089 0.90 CYP1A1 (0.45) MAPTRAB9ACYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10553800-B2 Condensed cyclic compound and an organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2020-02-04 US disclosed
US-20170194572-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-06 US disclosed
US-20170194572-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10553800-B2 Condensed cyclic compound and an organic light-emitting device including the same CRY1, CRY2, CCNT1 MAPT 1294/4885ALDH1A1 326/4885HPGD 1859/4885
US-20170194572-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNT1 MAPT 1294/4885ALDH1A1 326/4885HPGD 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.